文献速递心脑血管急症重症综合管理与镇静镇痛儿科与产科急症

危重患儿后部可逆性脑病综合征的特征与结局

Characteristics and Outcomes of Critically Ill Pediatric Patients with Posterior Reversible Encephalopathy Syndrome.
PubMed 文献 · Neurocrit Care · 2020-01-01
一句话结论危重患儿中,免疫抑制、自身免疫病、肾功能不全、贫血和高血压与PRES相关,PRES患儿病死率更高(15% vs 5%)且住院时间更长(13.1 vs 4.6天)。

该研究为2011至2016年某三级儿童医院收治的21岁以下PRES患儿的回顾性病历分析,以按年龄和儿童死亡风险指数2评分匹配的患儿为对照。PRES多表现为精神状态改变(75%)、癫痫发作(77%)、头痛(31%)和视力改变(23%);恢复者症状中位消退时间为3天(范围1-8天)。PRES组病死率更高(15% vs 5%,p<0.05)、平均住院时间更长(13.1 vs 4.6天),更常合并自身免疫病、免疫抑制和贫血(均p<0.05);所有PRES患儿均有II期高血压(对照组41%,p<0.05),平均肌酐为2.35 mg/dL(对照组0.90 mg/dL,p<0.05)。校正白蛋白后,PRES与低钙血症无关联;脓毒症在PRES组与对照组间无差异(53% vs 59%,p=1.00)。

要点

  • 危重患儿PRES常以精神状态改变(75%)和癫痫发作(77%)起病,恢复者症状中位3天(范围1-8天)消退。
  • PRES患儿病死率15% vs 对照5%(p<0.05),平均住院时间13.1 vs 4.6天,提示预后更差。
  • 所有PRES患儿均有II期高血压(对照41%,p<0.05),平均肌酐2.35 mg/dL vs 对照0.90 mg/dL(p<0.05)。
  • PRES与自身免疫病、免疫抑制、贫血相关(均p<0.05);校正白蛋白后与低钙血症无关联,与脓毒症也无关联(53% vs 59%,p=1.00)。
  • 无PRES患儿在末次随访时诊断为癫痫,已启用抗癫痫药者均在13个月内停药。

适用人群与场景

  • 某三级儿童医院2011至2016年收治的21岁以下、诊断为PRES的危重患儿,年龄5-17岁,46%为男性。
  • 对照为按年龄和儿童死亡风险指数2评分匹配的患儿。

研究设计与关键结果

  • 研究类型为回顾性病历分析,共识别13例患者的16次PRES发作,对照按年龄和儿童死亡风险指数2评分匹配。
  • PRES表现:精神状态改变75%、癫痫发作77%、头痛31%、视力改变23%;恢复者(n=11)症状中位消退时间3天(范围1-8天)。
  • PRES组病死率15% vs 对照组5%(p<0.05),平均住院时间13.1 vs 4.6天(p<0.05)。
  • PRES组更常合并自身免疫病(p<0.05)、免疫抑制(p<0.05)和贫血(p<0.05)。
  • 所有PRES患儿均有II期高血压,对照组为41%(p<0.05);PRES组平均肌酐2.35 mg/dL vs 对照组0.90 mg/dL(p<0.05)。
  • 脓毒症疑诊在PRES组为53%、对照组为59%(p=1.00);校正白蛋白后PRES与低钙血症无关联。
  • 无PRES患儿在末次随访时诊断为癫痫,已启用抗癫痫药者均在13个月内停药。

证据类型、等级与局限

  • 证据类型:回顾性病历分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在危重患儿中,合并免疫抑制、自身免疫病、肾功能不全、贫血和高血压时需警惕PRES,原文显示这些因素与PRES相关。
  • PRES患儿病死率更高(15% vs 5%)且住院时间更长(13.1 vs 4.6天),提示对这类患儿应加强监护。
  • 原文显示已启用抗癫痫药的PRES患儿均在13个月内停药,且无患儿在末次随访时诊断为癫痫。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND/OBJECTIVE: Posterior reversible encephalopathy syndrome (PRES) is a clinical and radiologic entity, typically manifesting as reversible neurological symptoms and signs of white matter edema on magnetic resonance imaging. PRES has been widely described in adults. Studies of PRES in children are mostly limited to case series and case controls.

METHODS: Retrospective chart review of patients under 21 years with PRES admitted at a tertiary children's hospital from 2011 to 2016. They were compared to controls matched for age and mortality risk using the Pediatric Index of Mortality-2 score. RESULTS: Sixteen cases of PRES were identified in 13 patients (ages 5-17 years, 46% male). PRES presented with altered mental status (75%), seizures (77%), headache (31%), and vision changes (23%). In patients who recovered (n = 11), median days to symptom resolution was three (range 1-8). PRES patients had a higher mortality rate (15% vs. 5%, p < 0.05) and higher mean length of stay (13.1 vs. 4.6 days) and were more likely to have autoimmune disease (p < 0.05), immunosuppression (p < 0.05), and anemia (p < 0.05). No PRES patients were diagnosed with epilepsy by last known follow-up, and all of whom had been started on an antiepileptic drug were discontinued within 13 months. Sepsis was suspected in 53% of PRES patients and 59% of controls (p = 1.00). All PRES patients had stage II hypertension, versus 41% of controls (p < 0.05). Average creatinine in PRES was 2.35 mg/dL compared to 0.90 mg/dL in controls (p < 0.05). PRES patients had lower serum calcium (p < 0.05). After correcting for albumin, no association between PRES and hypocalcemia remained. PRES patients had a higher length of stay (13.1 vs. 4.6 days, p < 0.05) and mortality rate (15% vs. 3%, p < 0.05).

CONCLUSIONS: Immunosuppression, autoimmune disease, renal insufficiency, anemia, and hypertension are associated with PRES after controlling for mortality risk in critically ill children. There was no association between corrected serum calcium and sepsis with PRES.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Fisler G, Monty MA, Kohn N, et al. Characteristics and Outcomes of Critically Ill Pediatric Patients with Posterior Reversible Encephalopathy Syndrome. Neurocrit Care. 2020. PMID: 31069660. doi:10.1007/s12028-019-00720-9

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。